Medtronic plc Stock

The stock market hasn't endured a deep bear market since the Great Recession. There have been corrections and bear markets since that point, but they have been brief affairs. With the market near

Amid the largest IPO in history, which we recently witnessed, and the booming artificial intelligence industry that continues to show highly attractive prospects, there remain serious economic and

Whether you believe there's a bubble in tech or are just worried about rising valuations in the stock market, there's ample reason to want to reduce risk right now. By diversifying into dividend

Investing in dividend stocks is a great way to earn superior returns over the long run. How do we know that? According to some research, most of the S&P 500's returns over the past several decades

Investing in healthcare hasn't been all that exciting an option for investors in recent years. But over the long term, it can lead to significant returns. Healthcare is not only essential but a

Medtronic (NYSE: MDT) is one of the world's largest medical technology companies, but it spent years on the outside looking in at the robotic-assisted surgery market. That officially changed in

Dividend stocks that raise their payouts routinely can be money-making machines for investors. You effectively get an increase in your dividend income from these investments by doing nothing, simply

Medtronic (NYSE: MDT) stock jumped 5.3% through 1:25 p.m. ET Wednesday after it "beat by a penny" on fiscal Q4 2026 earnings this morning, and beat on revenue as well.

Heading into the report

Even before Medtronic (NYSE:MDT) announced its fiscal fourth-quarter 2026 earnings, the company was telling Wall Street it was starting down a new path. That's a good thing, because the old path

There will be another recession in the near future, of that you can be certain. When it comes along is harder to determine. Given that consumers were already tightening their budgets before high oil

It's safe to say the healthcare sector isn't renowned as a repository of dividend-paying companies.

Yet some not only pay such monies steadily and reliably, but theirs are lofty enough to be

Even great companies go through hard times. In fact, very often, what makes a company great is its ability to navigate through difficulties. Medtronic's (NYSE: MDT) 48 consecutive annual dividend

The world is uncertain today, with geopolitical conflicts unfolding across multiple regions. The market is uncertain, with stocks at record highs despite consumer concerns about high costs and the

Shares of Medtronic (NYSE: MDT) are down 40% from their 2021 high. The dividend yield is a historically high 3.6%. Although this medical device maker is deeply unloved, now could be a good time for

One of the biggest reasons to include some exposure to healthcare in your portfolio is simple logic: Healthcare isn't optional. If someone is ill, they need to address the problem, because the

Intuitive Surgical (NASDAQ: ISRG) has a powerful business model. The core is its da Vinci surgical robot, but the real flywheel is the sale of parts and services for its robots. A leader in this

Dividend stocks can be valuable if you're a retiree or just want to boost your income. Many dividend stocks, however, don't pay a dividend every month. In most cases, you're waiting three months for

Some dividend payers suspend their dividend programs when they encounter headwinds, such as slower growth. Others double down and continue issuing regular payouts while they work out ways to

Some investors have watched their healthcare stock holdings drop in value recently or over the years, yet they have stuck around. That's because those companies are still paying dividends with

Boston Scientific (NYSE:BSX), a medical device developer, closed Wednesday at $64.87, up 8.99%. The stock is jumping after a Q1 earnings beat paired with lowered 2026 guidance. Investors are

Boston Scientific (NYSE:BSX), a maker of medical devices for interventional specialties, closed Monday at $62.92, down 9.03%. The stock moved lower on Monday as investors analyzed new clinical trial